Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Author Information
Author(s): Teresa Field, Claudio Anasetti
Primary Institution: H. Lee Moffitt Cancer Center and Research Institute
Hypothesis
What is the role and timing of hematopoietic cell transplantation (HCT) for patients with myelodysplastic syndrome (MDS)?
Conclusion
HCT remains the only curative therapy for high risk MDS, and reduced toxicity of pre-transplant conditioning regimens allows treatment for patients up to 75 years of age.
Supporting Evidence
- HCT is the only curative treatment for MDS.
- Age limitations for HCT have decreased due to reduced toxicity conditioning regimens.
- Patients with high risk IPSS had significantly lower relapse-free survival compared to low risk patients.
Takeaway
Hematopoietic cell transplantation is the best chance for curing myelodysplastic syndrome, especially for older patients who can now receive it with less risk.
Methodology
This review discusses the role of HCT for MDS based on prognostic features, optimal timing, and outcomes based on patient age.
Potential Biases
Potential bias in patient selection and treatment outcomes based on age and disease severity.
Limitations
The study does not provide data on the proportion of patients treated with DMTi who are eligible for HCT.
Participant Demographics
Most patients with MDS are older than 60 years.
Statistical Information
P-Value
0.020
Confidence Interval
95% CI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website